Literature DB >> 26449883

CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice.

Li Xu1, Ki Ho Park1, Lixia Zhao1, Jing Xu1, Mona El Refaey1, Yandi Gao1, Hua Zhu1, Jianjie Ma1, Renzhi Han1.   

Abstract

Duchenne muscular dystrophy (DMD) is a degenerative muscle disease caused by genetic mutations that lead to the disruption of dystrophin in muscle fibers. There is no curative treatment for this devastating disease. Clustered regularly interspaced short palindromic repeat/Cas9 (CRISPR/Cas9) has emerged as a powerful tool for genetic manipulation and potential therapy. Here we demonstrate that CRIPSR-mediated genome editing efficiently excised a 23-kb genomic region on the X-chromosome covering the mutant exon 23 in a mouse model of DMD, and restored dystrophin expression and the dystrophin-glycoprotein complex at the sarcolemma of skeletal muscles in live mdx mice. Electroporation-mediated transfection of the Cas9/gRNA constructs in the skeletal muscles of mdx mice normalized the calcium sparks in response to osmotic shock. Adenovirus-mediated transduction of Cas9/gRNA greatly reduced the Evans blue dye uptake of skeletal muscles at rest and after downhill treadmill running. This study provides proof evidence for permanent gene correction in DMD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26449883      PMCID: PMC4786912          DOI: 10.1038/mt.2015.192

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  30 in total

1.  Uncontrolled calcium sparks act as a dystrophic signal for mammalian skeletal muscle.

Authors:  Xu Wang; Noah Weisleder; Claude Collet; Jingsong Zhou; Yi Chu; Yutaka Hirata; Xiaoli Zhao; Zui Pan; Marco Brotto; Heping Cheng; Jianjie Ma
Journal:  Nat Cell Biol       Date:  2005-04-17       Impact factor: 28.824

Review 2.  Mechanisms of muscle degeneration, regeneration, and repair in the muscular dystrophies.

Authors:  Gregory Q Wallace; Elizabeth M McNally
Journal:  Annu Rev Physiol       Date:  2009       Impact factor: 19.318

3.  Correction of a genetic disease in mouse via use of CRISPR-Cas9.

Authors:  Yuxuan Wu; Dan Liang; Yinghua Wang; Meizhu Bai; Wei Tang; Shiming Bao; Zhiqiang Yan; Dangsheng Li; Jinsong Li
Journal:  Cell Stem Cell       Date:  2013-12-05       Impact factor: 24.633

4.  Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients.

Authors:  Gerald Schwank; Bon-Kyoung Koo; Valentina Sasselli; Johanna F Dekkers; Inha Heo; Turan Demircan; Nobuo Sasaki; Sander Boymans; Edwin Cuppen; Cornelis K van der Ent; Edward E S Nieuwenhuis; Jeffrey M Beekman; Hans Clevers
Journal:  Cell Stem Cell       Date:  2013-12-05       Impact factor: 24.633

5.  Measurement of sub-membrane [Ca2+] in adult myofibers and cytosolic [Ca2+] in myotubes from normal and mdx mice using the Ca2+ indicator FFP-18.

Authors:  Renzhi Han; Miranda D Grounds; Anthony J Bakker
Journal:  Cell Calcium       Date:  2006-06-12       Impact factor: 6.817

6.  Multiplex genome engineering using CRISPR/Cas systems.

Authors:  Le Cong; F Ann Ran; David Cox; Shuailiang Lin; Robert Barretto; Naomi Habib; Patrick D Hsu; Xuebing Wu; Wenyan Jiang; Luciano A Marraffini; Feng Zhang
Journal:  Science       Date:  2013-01-03       Impact factor: 47.728

7.  RNA-guided human genome engineering via Cas9.

Authors:  Prashant Mali; Luhan Yang; Kevin M Esvelt; John Aach; Marc Guell; James E DiCarlo; Julie E Norville; George M Church
Journal:  Science       Date:  2013-01-03       Impact factor: 47.728

Review 8.  Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.

Authors:  Annemieke Aartsma-Rus; Ivo Fokkema; Jan Verschuuren; Ieke Ginjaar; Judith van Deutekom; Gert-Jan van Ommen; Johan T den Dunnen
Journal:  Hum Mutat       Date:  2009-03       Impact factor: 4.878

9.  Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype.

Authors:  Hao Yin; Wen Xue; Sidi Chen; Roman L Bogorad; Eric Benedetti; Markus Grompe; Victor Koteliansky; Phillip A Sharp; Tyler Jacks; Daniel G Anderson
Journal:  Nat Biotechnol       Date:  2014-03-30       Impact factor: 54.908

10.  Disrupted membrane structure and intracellular Ca²⁺ signaling in adult skeletal muscle with acute knockdown of Bin1.

Authors:  Andoria Tjondrokoesoemo; Ki Ho Park; Christopher Ferrante; Shinji Komazaki; Sebastian Lesniak; Marco Brotto; Jae-Kyun Ko; Jingsong Zhou; Noah Weisleder; Jianjie Ma
Journal:  PLoS One       Date:  2011-09-30       Impact factor: 3.240

View more
  93 in total

1.  AAV CRISPR editing rescues cardiac and muscle function for 18 months in dystrophic mice.

Authors:  Chady H Hakim; Nalinda B Wasala; Christopher E Nelson; Lakmini P Wasala; Yongping Yue; Jacqueline A Louderman; Thais B Lessa; Aihua Dai; Keqing Zhang; Gregory J Jenkins; Michael E Nance; Xiufang Pan; Kasun Kodippili; N Nora Yang; Shi-Jie Chen; Charles A Gersbach; Dongsheng Duan
Journal:  JCI Insight       Date:  2018-12-06

Review 2.  Gene-targeting pharmaceuticals for single-gene disorders.

Authors:  Arthur L Beaudet; Linyan Meng
Journal:  Hum Mol Genet       Date:  2015-11-30       Impact factor: 6.150

3.  Effective regeneration of dystrophic muscle using autologous iPSC-derived progenitors with CRISPR-Cas9 mediated precise correction.

Authors:  Mackenzie Hagan; Muhammad Ashraf; Il-Man Kim; Neal L Weintraub; Yaoliang Tang
Journal:  Med Hypotheses       Date:  2017-11-23       Impact factor: 1.538

4.  BEAT: A Python Program to Quantify Base Editing from Sanger Sequencing.

Authors:  Li Xu; Yakun Liu; Renzhi Han
Journal:  CRISPR J       Date:  2019-07-18

5.  A New Kid on the Playground of CRISPR DMD Therapy.

Authors:  Dongsheng Duan
Journal:  Hum Gene Ther Clin Dev       Date:  2017-06       Impact factor: 5.032

6.  Gene Editing for Duchenne Muscular Dystrophy Using the CRISPR/Cas9 Technology: The Importance of Fine-tuning the Approach.

Authors:  Jacques P Tremblay; Jean-Paul Iyombe-Engembe; Benjamin Duchêne; Dominique L Ouellet
Journal:  Mol Ther       Date:  2016-11       Impact factor: 11.454

Review 7.  Pompe Disease: From Basic Science to Therapy.

Authors:  Lara Kohler; Rosa Puertollano; Nina Raben
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

8.  A recurrent COL6A1 pseudoexon insertion causes muscular dystrophy and is effectively targeted by splice-correction therapies.

Authors:  Véronique Bolduc; A Reghan Foley; Herimela Solomon-Degefa; Apurva Sarathy; Sandra Donkervoort; Ying Hu; Grace S Chen; Katherine Sizov; Matthew Nalls; Haiyan Zhou; Sara Aguti; Beryl B Cummings; Monkol Lek; Taru Tukiainen; Jamie L Marshall; Oded Regev; Dina Marek-Yagel; Anna Sarkozy; Russell J Butterfield; Cristina Jou; Cecilia Jimenez-Mallebrera; Yan Li; Corine Gartioux; Kamel Mamchaoui; Valérie Allamand; Francesca Gualandi; Alessandra Ferlini; Eric Hanssen; Steve D Wilton; Shireen R Lamandé; Daniel G MacArthur; Raimund Wagener; Francesco Muntoni; Carsten G Bönnemann
Journal:  JCI Insight       Date:  2019-03-21

9.  CRISPR/Cas9 Flexes Its Muscles: In Vivo Somatic Gene Editing for Muscular Dystrophy.

Authors:  Thierry VandenDriessche; Marinee K Chuah
Journal:  Mol Ther       Date:  2016-03       Impact factor: 11.454

10.  Questions Answered and Unanswered by the First CRISPR Editing Study in a Canine Model of Duchenne Muscular Dystrophy.

Authors:  Nalinda B Wasala; Chady H Hakim; Shi-Jie Chen; N Nora Yang; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2019-02-26       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.